Dr. Carsten Brunn to Lead Bayer's Pharmaceuticals Business in the Americas Region

News provided by

Jan 17, 2017, 08:00 ET

WHIPPANY, N.J., Jan. 17, 2017 /PRNewswire/ -- Bayer today announced the appointment of Dr. Carsten Brunn as President of its Pharmaceuticals business in the Americas, comprising the United States, Canada, Central and Latin America. In this role, Dr. Brunn will report to Dieter Weinand, member of the Board of Management of Bayer AG and President of the Pharmaceutical division.

"Carsten is a strategic and highly respected leader in the pharmaceutical industry and I'm delighted to have him lead the company's largest pharmaceutical business worldwide," said Dieter Weinand. "Carsten's global perspective and proven track record of successful operational execution at the local level will be a critical asset to us as we continue to build on our current momentum in the U.S. and across the Americas region."

Previously, Dr. Brunn was Head of Bayer's Pharmaceuticals Commercial Operations in Japan, a role he held since 2013. He served as the Chairman of European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan, an organization representing 24 R&D-based innovative pharmaceutical companies in Japan. Dr. Brunn joined Bayer in 2011 as Global Head of Primary Care based in Beijing, China. Prior to joining Bayer, Dr. Brunn held a number of senior leadership roles at companies including Eli Lilly, Novartis, and Bausch & Lomb in Europe, Asia, and the United States.

"It has been an incredibly rewarding experience to lead Bayer's pharmaceuticals organization in Japan, and I am honored to have the opportunity to join such an established team here in the United States," said Carsten Brunn. "The U.S. is one of the most important and innovative pharmaceutical markets in the world, where we are in a solid period of consistent growth with strong performance across all our therapeutic areas. I'm thrilled to bring my experiences from other markets to this organization as we continue to build on our strengths and meet the needs of patients."

Dr. Brunn graduated from the University of Freiburg in Germany with a Master of Science in Pharmaceutical Science. In addition, he studied at the University of Washington under a research scholarship and later received his PhD in Chemistry from the University of Hamburg in Germany. He completed his executive education at the London Business School.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.

Our online press service is just a click away: press.bayer.com
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: https://twitter.com/BayerPharma

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

SOURCE Bayer